CL2022003725A1 - Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6. - Google Patents

Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.

Info

Publication number
CL2022003725A1
CL2022003725A1 CL2022003725A CL2022003725A CL2022003725A1 CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1 CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1
Authority
CL
Chile
Prior art keywords
treatment
activity
diseases associated
aberrant
interleukin
Prior art date
Application number
CL2022003725A
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/ru
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of CL2022003725A1 publication Critical patent/CL2022003725A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2022003725A 2020-06-26 2022-12-22 Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6. CL2022003725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (ru) 2020-06-26 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Publications (1)

Publication Number Publication Date
CL2022003725A1 true CL2022003725A1 (es) 2023-05-19

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003725A CL2022003725A1 (es) 2020-06-26 2022-12-22 Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.

Country Status (6)

Country Link
CN (1) CN115803026A (zh)
BR (1) BR112022026356A2 (zh)
CL (1) CL2022003725A1 (zh)
CO (1) CO2023000604A2 (zh)
MA (1) MA58653B1 (zh)
WO (1) WO2021262040A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023249516A1 (ru) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новая кристаллическая форма 1-[2-(1-метилимидазол-4-ил)этил]пергидроазин-2,6-диона и ее фармацевтическое применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN102432544B (zh) * 2011-11-17 2014-05-21 天津医科大学 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
MD4802C1 (ro) * 2017-09-07 2022-11-30 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
TW202203917A (zh) * 2020-04-13 2022-02-01 加拿大健康網路大學 治療細胞激素釋放症候群之方法
CN113582980B (zh) * 2020-04-30 2023-11-24 上海科技大学 基于杂环和戊二酰亚胺骨架的化合物及其应用

Also Published As

Publication number Publication date
CN115803026A (zh) 2023-03-14
WO2021262040A1 (ru) 2021-12-30
MA58653B1 (fr) 2024-02-29
BR112022026356A2 (pt) 2023-01-17
RU2020121363A (ru) 2021-12-27
RU2020121363A3 (zh) 2021-12-27
CO2023000604A2 (es) 2023-01-26
MA58653A1 (fr) 2023-07-31

Similar Documents

Publication Publication Date Title
CL2022003725A1 (es) Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
PA8635201A1 (es) Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
ECSP12011638A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
MA37405A1 (fr) Composés hétérocyclyle
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
HN2012001037A (es) Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
EA201001857A1 (ru) Фармацевтическая лекарственная форма для немедленного высвобождения производного индолинона
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CL2011002181A1 (es) Compuestos ciclicos o heterociclicos (n,o,s) de derivados de fenil (heterociclil) fenil (metil,etil) amina, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso para el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia a la glucosa e hiperlipidemia, entre otras enfermedades.
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
ECSP088257A (es) Derivados de amida